Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 5/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 5/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 5/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.38 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.38 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810020 | 1.00 | ABCB11 (0.41) | ABCB11ACACBPDK1PDK2PDK3 | |
| SCHEMBL6540415 | 0.88 | CNR1 (0.40) | ACACBCNR1ESR1KCNH2ABCC9 | |
| SCHEMBL6540853 | 0.88 | ESR1 (0.42) | ACACBCNR1ESR1KCNH2ABCC9 | |
| SCHEMBL6540590 | 0.86 | ACACB (0.45) | ACACBPDK1PDK2PDK3PDK4 | |
| SCHEMBL6806001 | 0.86 | ACACB (0.45) | ACACBPDK1PDK2PDK3PDK4 | |
| SCHEMBL6677754 | 0.86 | ALDH1A1 (0.42) | ACACBCNR1ESR1KCNH2GAA | |
| SCHEMBL6800681 | 0.86 | ALDH1A1 (0.42) | ACACBCNR1ESR1KCNH2GAA | |
| SCHEMBL6541437 | 0.85 | ESR1 (0.46) | ACACBCNR1ESR1KCNH2ABCC9 | |
| SCHEMBL6539913 | 0.85 | ESR1 (0.46) | ACACBCNR1ESR1KCNH2ABCC9 | |
| SCHEMBL6805794 | 0.84 | MAPT (0.42) | ACACBCNR1ESR1KCNH2ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | ABCB11 1184/4885ACACB 3020/4885PDK1 2885/4885 |
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | ABCB11 1249/4885ACACB 1800/4885PDK1 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.